Efficacy of Locally Delivered Simvastatin Combined with Autologous Platelet-rich Fibrin in Treatment of Intrabony Defects: A Randomized Controlled Clinical Trial
Kommula M Meghana Devi, Gautami S Penmetsa, Arun Bhupathi, Sruthima NVS Gottumukkala, Mohan K Pasupulet, Vivek Bypalli, Krishna C Patri
Citation Information :
Devi KM, Penmetsa GS, Bhupathi A, Gottumukkala SN, Pasupulet MK, Bypalli V, Patri KC. Efficacy of Locally Delivered Simvastatin Combined with Autologous Platelet-rich Fibrin in Treatment of Intrabony Defects: A Randomized Controlled Clinical Trial. World J Dent 2024; 15 (3):201-207.
Aim: This study aimed to assess and compare, in the context of surgical therapy of intraosseous defects, the regeneration capacity of platelet-rich fibrin (PRF) alone vs PRF plus simvastatin (SMV).
Materials and methods: A total of 30 sites in 15 participants with bilateral interproximal intraosseous defects on radiographs with moderate-to-severe periodontitis were randomly assigned to control (PRF) and test (SMV + PRF) groups. Plaque index (PI), gingival index (GI), probing pocket depth (PPD), clinical attachment level (CAL), and gingival recession (GR) were recorded at baseline, 3 months, and 6 months. Reduction in defect depth (DD) and amount of osseous fill was evaluated radiographically from baseline to 3 and 6 months.
Results: Every clinical measure was reduced in both groups in a statistically significant way. The mean amount of osseous fill at 6 months was statistically significantly higher in the test group.
Conclusion: It can be concluded that both groups showed definitive improvement in all parameters. When SMV + PRF was utilized to treat alveolar defects, however, the group's outcomes were noticeably improved in terms of both clinical and radiographic criteria.
Clinical significance: Simvastatin (SMV) has the potential to aid in regeneration and has shown itself to be a cost-effective and secure substitute for traditional grafting techniques.
Kao RT, Nares S, Reynolds MA. Periodontal regeneration - intrabony defects: a systematic review from the AAP Regeneration Workshop. J Periodontol 2015;86(2 Suppl):S77–104. DOI: 10.1902/jop.2015.130685
Shaju JP, Zade RM, Das M. Prevalence of periodontitis in the Indian population: a literature review. J Indian Soc Periodontol 2011;15(1):29–34. DOI: 10.4103/0972-124X.82261
Nazir MA. Prevalence of periodontal disease, its association with systemic diseases and prevention. Int J Health Sci (Qassim) 2017;1(2):72–80. PMID: 28539867.
Lekovic V, Camargo PM, Weinlaender M, et al. The use of bovine porous bone mineral in combination with enamel matrix proteins or with an autologous fibrinogen/fibronectin system in the treatment of intrabony periodontal defects in humans. J Periodontol 2001;72(9):1157–1163. DOI: 10.1902/jop.2000.72.9.1157
Laurell L, Gottlow J, Zybutz M, et al. Treatment of intrabony defects by different surgical procedures. A literature review. J Periodontol 1998;69(3):303–313. DOI: 10.1902/jop.1998.69.3.303
Chandran P, Sivadas A. Platelet-rich fibrin: its role in periodontal regeneration. Saudi Dent J 2014;5(2):117–122. DOI: 10.1016/j.ksujds.2013.09.001
Bakhtiar H, Esmaeili S, Fakhr Tabatabayi S, et al. Second-generation platelet concentrate (platelet-rich fibrin) as a scaffold in regenerative endodontics: a case series. J Endod 2017;43(3):401–408. DOI: 10.1016/j.joen.2016.10.016
Prakash S, Thakur A. Platelet concentrates: past, present and future. J Maxillofac Oral Surg 2011;10(1):45–49. DOI: 10.1007/s12663-011-0182-4
Petit C, Batool F, Bugueno IM, et al. Contribution of statins towards periodontal treatment: a review. Mediators Inflamm 2019;2019:6367402. DOI: 10.1155/2019/6367402
Chung YS, Lee MD, Lee SK, et al. HMG-CoA reductase inhibitors increase BMD in type 2 diabetes mellitus patients. J Clin Endocrinol Metab 2000;85(3):1137–1142. DOI: 10.1210/jcem.85.3.6476
Davignon J, Laaksonen R. Low-density lipoprotein-independent effects of statins. Curr Opin Lipidol 1999;10(6):543–559. DOI: 10.1097/00041433-199912000-00010
S Martande S, Kumari M, Pradeep AR, et al. Comparative evaluation of efficacy of subgingivally delivered 1.2% atorvastatin and 1.2% simvastatin in the treatment of intrabony defects in chronic periodontitis: a randomized controlled trial. J Dent Res Dent Clin Dent Prospects 2017;11(1):18–25. DOI: 10.15171/joddd.2017.004
Shah M, Muley P, Muley A. Are statins worthy for treatment of periodontitis? A systematic review and meta-analysis. Adv Hum Biol 2017;7(1):8–14. DOI: 10.4103/2321-8568.199531
Pradeep AR, Thorat MS. Clinical effect of subgingivally delivered simvastatin in the treatment of patients with chronic periodontitis: a randomized clinical trial. J Periodontol 2010;81(2):214–222. DOI: 10.1902/jop.2009.090429
Agarwal S, Chaubey KK, Chaubey A, et al. Clinical efficacy of subgingivally delivered simvastatin gel in chronic periodontitis patients. J Indian Soc Periodontol 2016;20(4):409–416. DOI: 10.4103/0972-124X.194270
Pradeep AR, Priyanka N, Kalra N, et al. Clinical efficacy of subgingivally delivered 1.2-mg simvastatin in the treatment of individuals with class II furcation defects: a randomized controlled clinical trial. J Periodontol 2012;83(12):1472–1479. DOI: 10.1902/jop.2012.110716
Surve SM, Acharya AB, Thakur SL. Efficacy of subgingivally delivered atorvastatin and simvastatin as an adjunct to scaling and root planing. Drug Metab Pers Ther 2015;30(4):263–269. DOI: 10.1515/dmpt-2015-0024
Ranjan R, Patil SR, H R V. Effect of in-situ application of simvastatin gel in surgical management of osseous defects in chronic periodontitis-a randomized clinical trial. J Oral Biol Craniofac Res 2017;7(2):113–118. DOI: 10.1016/j.jobcr.2017.05.005
King GN, Hughes FJ. Bone morphogenetic protein-2 stimulates cell recruitment and cementogenesis during early wound healing. J Clin Periodontol 2001;28(5):465–475. DOI: 10.1034/j.1600-051x.2001.028005465.x
Fisher JE, Rogers MJ, Halasy JM, et al. Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. Proc Natl Acad Sci U S A 1999;96(1):133–138. DOI: 10.1073/pnas.96.1.133
Maniyar N, Sarode GS, Sarode SC, et al. Platelet-rich fibrin: a ”wonder material” in advanced surgical dentistry. Med J DY Patil Vidyapeeth 2018;11(4):287–290. DOI: 10.4103/MJDRDYPU.MJDRDYPU_204_17
Cunha-Cruz J, Saver B, Maupome G, et al. Statin use and tooth loss in chronic periodontitis patients. J Periodontol 2006;77(6):1061–1066. DOI: 10.1902/jop.2006.050280
Cao R, Li Q, Chen Y, et al. Efficacy of locally-delivered statins adjunct to non-surgical periodontal therapy for chronic periodontitis: a Bayesian network analysis. BMC Oral Health 2019;19(1):105. DOI: 10.1186/s12903-019-0789-2
Sharma P, Singh A, Mallapragada S. Sub-gingival delivery of simvastatin and rosuvastatin for treatment of chronic periodontitis with diabetes mellitus: A randomized controlled clinical-radiographic pilot study. J Oral Biol Craniofac Res 2023;13(2):315–320. DOI: 10.1016/j.jobcr.2023.02.012
Gupta S, Verma P, Tikku AP, et al. ”Effect of local application of simvastatin in bone regeneration of peri-apical defects-a clinico-radiographic study. J Oral Biol Craniofac Res 2020;10(4):583–591. DOI: 10.1016/j.jobcr.2020.08.014
Gautam K, Kapoor A, Mathur S, et al. Comparative evaluation of autogenous bone graft and autologous platelet-rich fibrin with and without 1.2 mg in situ rosuvastatin gel in the surgical treatment of intrabony defect in chronic periodontitis patients. Contemp Clin Dent 2022;13(1):69–77. DOI: 10.4103/ccd.ccd_740_20
Grover HS, Luthra S, Maroo S. Are statins really wonder drugs? J Formos Med Assoc 2014;113(12):892–898. DOI: 10.1016/j.jfma.2013.05.016
